Overview |
bs-23550R-APC-Cy7 |
NCR1 Polyclonal Antibody, APC-Cy7 Conjugated |
IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse |
Specifications |
APC-Cy7 |
Rabbit |
KLH conjugated synthetic peptide derived from human NCR1 |
1-100/304 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
O76036 |
9437 |
Cell membrane |
Natural killer cell p46-related protein; Natural cytotoxicity triggering receptor 1; NK-p46; NKp46; NK cell-activating receptor; Lymphocyte antigen 94 homolog; CD335; CD 335; LY94; NCTR1_HUMAN. |
The natural cytotoxicity receptors (NCRs) are a recently characterized family of Ig-like activation receptors that appear to be major triggering receptors in tumor cell recognition. NCR1 is a glycoprotein that has two extracellular Ig-like domains followed by a ~40 amino acid residue stalk region, a type I transmembrane domain, and a short cytoplasmic tail. NCR1 has been shown to represent a novel NK cell-specific molecule involved in human NK cell activation. NCR1 has been implicated in NK cell-mediated lysis of several autologous tumor cells and pathogen-infected cell lines. |
Application Dilution |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |